Product Code: 55927
The blood glucose monitoring market is expected to register a CAGR of 10% during the forecast period of 2020-2025. The market is estimated to reach a value of USD 13.7 billion by 2020.
- Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices.
- Obesity is also considered as one of the major factors contributing to the disease, primarily Type 2 diabetes.
- Also, other factors, such as technological innovations and advancements, give many conveniences in measuring blood glucose levels. One such advancement in monitoring the blood glucose level is established with continuous glucose monitoring devices.
- These devices help in the early detection of hypo and hyperglycemic conditions.This favor is expected to drive the market for glucose monitoring.
Key Market Trends
Glucometer consumables (test strips and lancets) occupy highest market share
Although CGM is an advanced way for people living with diabetes to check glucose readings in real-time, SMBG is the most preferred device by the patients due to its economic affordability and less sophisticated usage when compared to CGM. The SBGM occupies more than 87% of the share in the blood glucose monitoring market. The further segmented market of SBGM gives an understanding that the disposable consumables - test strips and lancets, occupy the larger market share, compared to glucometer devices. However, the CAGR for glucometer devices is high. CGM, though it provides real-time data of blood glucose levels for patients, has low adaptability in the emerging markets. However, CGM's adaptability is high in developed markets. The cost factor is a major concern for the stunted growth of CGM in emerging markets.
North America is leading the market
In 2019, North America, especially the United States, held the largest share in the blood glucose monitoring market, due to the large patient pool and wide acceptance of advanced technologies followed by Europe, with moderate growth. Asia-Pacific, Latin America, and the Middle East & Africa witnessed low growth, due to economic affordability.
Competitive Landscape
The blood glucose monitoring market is highly fragmented, with few major manufacturers present in the market. Mergers and acquisitions among the players in the recent past helped the companies to strengthen their market presence. For example, Dexcom partnered with Julphar to increase its presence in the Middle Eastern region.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 Self-monitoring blood glucose devices (Value and Volume, 2012-2025)
- 5.1.1 By Component
- 5.1.1.1 Glucometer Devices
- 5.1.1.2 Test Strips
- 5.1.1.3 Lancets
- 5.1.2 By End Use
- 5.1.2.1 Hospital (Value and Volume, 2012-2025)
- 5.1.2.1.1 Glucometer Devices
- 5.1.2.1.2 Test Strips
- 5.1.2.1.3 Lancets
- 5.1.2.2 Personal (Value and Volume, 2012-2025)
- 5.1.2.2.1 Glucometer Devices
- 5.1.2.2.2 Test Strips
- 5.1.2.2.3 Lancets
- 5.2 Continuous blood glucose monitoring devices (Value and Volume, 2012-2025)
- 5.2.1 By Component
- 5.2.1.1 Sensors
- 5.2.1.2 Durables (Receivers and Transmitters)
- 5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States (Value and Volume, 2012-2025)
- 5.3.1.1.1 Self-monitoring Blood Glucose Devices
- 5.3.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
- 5.3.1.1.1.2 By End User (Hospital and Personal)
- 5.3.1.1.2 Continuous Glucose Monitoring devices
- 5.3.1.1.2.1 By Component (Sensors and Receivers)
- 5.3.1.2 Canada (Value and Volume, 2012-2025)
- 5.3.1.2.1 Self-monitoring blood glucose devices
- 5.3.1.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.1.2.1.2 By End User (Hospital and Personal)
- 5.3.1.2.2 Continuous Glucose Monitoring
- 5.3.1.2.2.1 By Component (Sensors and Receivers)
- 5.3.1.3 Rest of North America (Value and Volume, 2012-2025)
- 5.3.1.3.1 Self-monitoring blood glucose devices
- 5.3.1.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.1.3.1.2 By End User (Hospital and Personal)
- 5.3.1.3.2 Continuous Glucose Monitoring
- 5.3.1.3.2.1 By Component (Sensors and Receivers)
- 5.3.2 Europe
- 5.3.2.1 France (Value and Volume, 2012-2025)
- 5.3.2.1.1 Self-monitoring Blood Glucose Devices
- 5.3.2.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.1.1.2 By End User (Hospital and Personal)
- 5.3.2.1.2 Continuous Glucose Monitoring
- 5.3.2.1.2.1 By Component (Sensors and Receivers)
- 5.3.2.2 Germany (Value and Volume, 2012-2025)
- 5.3.2.2.1 Self-monitoring Blood Glucose Devices
- 5.3.2.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.2.1.2 By End User (Hospital and Personal)
- 5.3.2.2.2 Continuous Glucose Monitoring
- 5.3.2.2.2.1 By Component (Sensors and Receivers)
- 5.3.2.3 Italy (Value and Volume, 2012-2025)
- 5.3.2.3.1 Self-monitoring blood glucose devices
- 5.3.2.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.3.1.2 By End User (Hospital and Personal)
- 5.3.2.3.2 Continuous Glucose Monitoring
- 5.3.2.3.2.1 By Component (Sensors and Receivers)
- 5.3.2.4 Spain (Value and Volume, 2012-2025)
- 5.3.2.4.1 Self-monitoring blood glucose devices
- 5.3.2.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.4.1.2 By End User (Hospital and Personal)
- 5.3.2.4.2 Continuous Glucose Monitoring
- 5.3.2.4.2.1 By Component (Sensors and Receivers)
- 5.3.2.5 United Kingdom (Value and Volume, 2012-2025)
- 5.3.2.5.1 Self-monitoring blood glucose devices
- 5.3.2.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.5.1.2 By End User (Hospital and Personal)
- 5.3.2.5.2 Continuous Glucose Monitoring
- 5.3.2.5.2.1 By Component (Sensors and Receivers)
- 5.3.2.6 Russia (Value and Volume, 2012-2025)
- 5.3.2.6.1 Self-monitoring blood glucose devices
- 5.3.2.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.6.1.2 By End User (Hospital and Personal)
- 5.3.2.6.2 Continuous Glucose Monitoring
- 5.3.2.6.2.1 By Component (Sensors and Receivers)
- 5.3.2.7 Rest of Europe (Value and Volume, 2012-2025)
- 5.3.2.7.1 Self-monitoring blood glucose devices
- 5.3.2.7.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.2.7.1.2 By End User (Hospital and Personal)
- 5.3.2.7.2 Continuous Glucose Monitoring
- 5.3.2.7.2.1 By Component (Sensors and Receivers)
- 5.3.3 Latin America
- 5.3.3.1 Mexico (Value and Volume, 2012-2025)
- 5.3.3.1.1 Self-monitoring Blood Glucose Devices
- 5.3.3.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.3.1.1.2 By End User (Hospital and Personal)
- 5.3.3.1.2 Continuous Glucose Monitoring
- 5.3.3.1.2.1 By Component (Sensors and Receivers)
- 5.3.3.2 Brazil (Value and Volume, 2012-2025)
- 5.3.3.2.1 Self-monitoring Blood Glucose Devices
- 5.3.3.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.3.2.1.2 By End User (Hospital and Personal)
- 5.3.3.2.2 Continuous Glucose Monitoring
- 5.3.3.2.2.1 By Component (Sensors and Receivers)
- 5.3.3.3 Rest of Latin America (Value and Volume, 2012-2025)
- 5.3.3.3.1 Self-monitoring Blood Glucose Devices
- 5.3.3.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.3.3.1.2 By End User (Hospital and Personal)
- 5.3.3.3.2 Continuous Glucose Monitoring
- 5.3.3.3.2.1 By Component (Sensors and Receivers)
- 5.3.4 Asia-Pacific
- 5.3.4.1 Japan (Value and Volume, 2012-2025)
- 5.3.4.1.1 Self-monitoring Blood Glucose Devices
- 5.3.4.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.1.1.2 By End User (Hospital and Personal)
- 5.3.4.1.2 Continuous Glucose Monitoring
- 5.3.4.1.2.1 By Component (Sensors and Receivers)
- 5.3.4.2 South Korea (Value and Volume, 2012-2025)
- 5.3.4.2.1 Self-monitoring Blood Glucose Devices
- 5.3.4.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.2.1.2 By End User (Hospital and Personal)
- 5.3.4.2.2 Continuous Glucose Monitoring
- 5.3.4.2.2.1 By Component (Sensors and Receivers)
- 5.3.4.3 China (Value and Volume, 2012-2025)
- 5.3.4.3.1 Self-monitoring Blood Glucose Devices
- 5.3.4.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.3.1.2 By End User (Hospital and Personal)
- 5.3.4.3.2 Continuous Glucose Monitoring
- 5.3.4.3.2.1 By Component (Sensors and Receivers)
- 5.3.4.4 India (Value and Volume, 2012-2025)
- 5.3.4.4.1 Self-monitoring Blood Glucose Devices
- 5.3.4.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.4.1.2 By End User (Hospital and Personal)
- 5.3.4.4.2 Continuous Glucose Monitoring
- 5.3.4.4.2.1 By Component (Sensors and Receivers)
- 5.3.4.5 Australia (Value and Volume, 2012-2025)
- 5.3.4.5.1 Self-monitoring Blood Glucose Devices
- 5.3.4.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.5.1.2 By End User (Hospital and Personal)
- 5.3.4.5.2 Continuous Glucose Monitoring
- 5.3.4.5.2.1 By Component (Sensors and Receivers)
- 5.3.4.6 Vietnam (Value and Volume, 2012-2025)
- 5.3.4.6.1 Self-monitoring Blood Glucose Devices
- 5.3.4.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.6.1.2 By End User (Hospital and Personal)
- 5.3.4.6.2 Continuous Glucose Monitoring
- 5.3.4.6.2.1 By Component (Sensors and Receivers)
- 5.3.4.7 Malaysia (Value and Volume, 2012-2025)
- 5.3.4.7.1 Self-monitoring Blood Glucose Devices
- 5.3.4.7.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.7.1.2 By End User (Hospital and Personal)
- 5.3.4.7.2 Continuous Glucose Monitoring
- 5.3.4.7.2.1 By Component (Sensors and Receivers)
- 5.3.4.8 Indonesia (Value and Volume, 2012-2025)
- 5.3.4.8.1 Self-monitoring Blood Glucose Devices
- 5.3.4.8.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.8.1.2 By End User (Hospital and Personal)
- 5.3.4.8.2 Continuous Glucose Monitoring
- 5.3.4.8.2.1 By Component (Sensors and Receivers)
- 5.3.4.9 Philippines (Value and Volume, 2012-2025)
- 5.3.4.9.1 Self-monitoring Blood Glucose Devices
- 5.3.4.9.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.9.1.2 By End User (Hospital and Personal)
- 5.3.4.9.2 Continuous Glucose Monitoring
- 5.3.4.9.2.1 By Component (Sensors and Receivers)
- 5.3.4.10 Thailand (Value and Volume, 2012-2025)
- 5.3.4.10.1 Self-monitoring Blood Glucose Devices
- 5.3.4.10.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.10.1.2 By End User (Hospital and Personal)
- 5.3.4.10.2 Continuous Glucose Monitoring
- 5.3.4.10.2.1 By Component (Sensors and Receivers)
- 5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)
- 5.3.4.11.1 Self-monitoring Blood Glucose Devices
- 5.3.4.11.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.4.11.1.2 By End User (Hospital and Personal)
- 5.3.4.11.2 Continuous Glucose Monitoring
- 5.3.4.11.2.1 By Component (Sensors and Receivers)
- 5.3.5 Middle-East and Africa
- 5.3.5.1 Saudi Arabia (Value and Volume, 2012-2025)
- 5.3.5.1.1 Self-monitoring Blood Glucose Devices
- 5.3.5.1.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.1.1.2 By End User (Hospital and Personal)
- 5.3.5.1.2 Continuous Glucose Monitoring
- 5.3.5.1.2.1 By Component (Sensors and Receivers)
- 5.3.5.2 Iran (Value and Volume, 2012-2025)
- 5.3.5.2.1 Self-monitoring Blood Glucose Devices
- 5.3.5.2.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.2.1.2 By End User (Hospital and Personal)
- 5.3.5.2.2 Continuous Glucose Monitoring
- 5.3.5.2.2.1 By Component (Sensors and Receivers)
- 5.3.5.3 Egypt (Value and Volume, 2012-2025)
- 5.3.5.3.1 Self-monitoring Blood Glucose Devices
- 5.3.5.3.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.3.1.2 By End User (Hospital and Personal)
- 5.3.5.3.2 Continuous Glucose Monitoring
- 5.3.5.3.2.1 By Component (Sensors and Receivers)
- 5.3.5.4 Oman (Value and Volume, 2012-2025)
- 5.3.5.4.1 Self-monitoring Blood Glucose Devices
- 5.3.5.4.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.4.1.2 By End User (Hospital and Personal)
- 5.3.5.4.2 Continuous Glucose Monitoring
- 5.3.5.4.2.1 By Component (Sensors and Receivers)
- 5.3.5.5 South Africa (Value and Volume, 2012-2025)
- 5.3.5.5.1 Self-monitoring Blood Glucose Devices
- 5.3.5.5.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.5.1.2 By End User (Hospital and Personal)
- 5.3.5.5.2 Continuous Glucose Monitoring
- 5.3.5.5.2.1 By Component (Sensors and Receivers)
- 5.3.5.6 Rest of Middle and Africa (Value and Volume, 2012-2025)
- 5.3.5.6.1 Self-monitoring Blood Glucose Devices
- 5.3.5.6.1.1 By Component (Glucometer Device, Test strips, and Lancets)
- 5.3.5.6.1.2 By End User (Hospital and Personal)
- 5.3.5.6.2 Continuous Glucose Monitoring
- 5.3.5.6.2.1 By Component (Sensors and Receivers)
6 MARKET INDICATORS
- 6.1 Type-1 Diabetes population (2012-2025)
- 6.2 Type-2 Diabetes population (2012-2025)
7 COMPETITIVE LANDSCAPE
- 7.1 COMPANY PROFILES
- 7.1.1 Abbott Diabetes Care
- 7.1.2 Roche Holding AG
- 7.1.3 Johnson & Johnson
- 7.1.4 Dexcom Inc.
- 7.1.5 Medtronic PLC
- 7.1.6 Arkray Inc.
- 7.1.7 Ascensia Diabetes Care
- 7.1.8 Agamatrix Inc.
- 7.1.9 Bionime Corporation
- 7.1.10 Acon Laboratories Inc.
- 7.1.11 Medisana AG
- 7.1.12 Trivida Functional Medicine
- 7.1.13 Rossmax International Ltd
- 7.2 COMPANY SHARE ANALYSIS
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
